

Program

Vaccines Summit-2023 | November 13-15 | Boston, MA

Keynote Presentations | Day-1 Nov-13 |

EST (Eastern Time Zone)

Bronze Sponsor



Exhibitors



Registrations

Introduction: Opening Ceremony

Session Chair: David Weiner, Executive Vice President, The Wistar Institute, Director, Vaccine & Immunotherapy Center

- 08:00-08:30 Prospects for Vaccination against human cytomegalovirus
Stanley A. Plotkin, Consultant and Emeritus Professor of the University of Pennsylvania, Vaxconsult, LLP (Pre-recorded presentation)
- 08:30-09:00 Development of a COVID-19 vaccine
Sir Andrew J. Pollard, Ashall Professor of Paediatric Infection and Immunity and Director of Oxford Vaccine Group

- 09:00-09:30 Correlates of protection for COVID-19 vaccines
Dan Barouch, Director, Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center
- 09:30-10:00 Presentation Title:
Ofer Levy, Staff Physician & Principal Investigator, Director, Precision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital Professor, Harvard Medical School
 Coffee Break 10:00-10:20
- 10:20-10:50 Presentation Title:
Walter Straus, Vice-President, Clinical Safety, Moderna
- 10:50-11:20 Nanoparticle intranasal vaccine prevents forward airborne transmission to naïve recipient hamsters
Jay A. Berzofsky, National Cancer Institute, NIH
- 11:20-11:50
 Translating pandemic R&D learnings into the broader global health agenda and preparedness
Sue Ann Costa Clemens, Professor of Global Health and Vaccinology at the University of Oxford and the University of Siena
- 11:50-12:20 Use of VSV vaccine platform for epidemic preparedness and response; update from current studies and innovative partnership strategies
Swati Gupta, VP, Emerging Infectious Diseases and Epidemiology, IAVI
- 12:20-12:50 NIAID, vaccine research center's pandemic preparedness and emergency response: Looking at the past to shape our future
Karin Bok, Acting Deputy Director, Director of Pandemic Preparedness and Emergency Response, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
 Lunch Break 12:50-14:00
- 14:00-14:30 Translating the COVID-19 learnings into long-lasting innovation: how new technologies could help address global health issues and improve pandemic preparedness
Ruben Rizzi, Vice President of Global Regulatory Affairs, BioNTech
- 14:30-15:00 Ad26 viral vector based vaccines for COVID-19 and HIV-1
Hanneke Schuitemaker, VP, Head of Viral Vaccine Discovery and Translational Medicine, Janssen Vaccines and Prevention B.V
- 15:00-15:30 Developments in the science of vaccine acceptance
Saad B. Omer, Founding Dean, Peter O'Donnell Jr. School of Public Health at UT Southwestern
- 15:30-16:00 Next generation mRNA Design-Increasing mRNA Potency with a New Cap Analog
Kate Broderick, Chief Innovation Officer, Maravai LifeSciences
 Coffee Break 16:00-16:20

16:20-16:50 Durable immunity, lessons from measles and mumps

Richard B. Kennedy, Professor of Medicine, Co-Director, Mayo Clinic Vaccine Research Group

16:50-17:20 Presentation Title:

David Weiner, Executive Vice President, Director, Vaccine & Immunotherapy Center,
The Wistar Institute

17:20-17:50 UVC: Universal Vaccine Cell

Tom Henley, Chief Scientific Officer, Intima Bioscience

17:50-18:20 A strategic model and industry collaboration for sustainable development of vaccines against neglected diseases

Francesco Berlanda Scorza, VP, Global Health R&D Vaccines Head and GVGH Institute
Director, GSK Vaccines Institute for Global Health

18:20-19:30

Reception

18:20-19:30

Poster Presentations

Neutralization of contemporary omicron subvariants after bivalent booster and XBB.1.5 breakthrough infections

Ping Ren, University of Texas Medical Branch

Neoantigen adenoviral cancer vaccine generates improved CD8+ T-cell responses compared to conventional peptide vaccine

Gabriel Dagotto, Harvard University

Vaccine Countermeasure Development at the Biomedical Advanced Research and Development

Authority (BARDA)

Rushyannah Killens-Cade, Biomedical Advanced Research and Development Authority (BARDA)

Advanced imaging techniques for pre-clinical differentiation of enabled vaccine formulations

Michael McNevin, Merck and Co., Inc

Concurrent administration of COVID-19 and influenza vaccines enhances spike-specific antibody responses

Susanna Barouch, Ragon Institute of MGH, MIT, and Harvard

A systems serology- and structural biology-based approach to identify humoral correlates of viral clearance

Ryan P McNamara, Ragon Institute of MGH, MIT, and Harvard

Development of an anti-ang2 vaccine and characterization of its effects on AVMs in BMP9/10-deficient mice

Sima Qutaina, Feinstein Institutes for Medical Research

C1 gene expression platform: Rapid, high yield, and lower cost way to develop and manufacture biologics

Mark Emaflarb, Dyadic International Inc

Development of a novel *Shigella* quadrivalent conjugate vaccine using O-polysaccharide and IpaB carrier protein

Shagndong Guo, Inventprise Inc

Compartmentalized vaccine responses in the intestine during murine norovirus infection

Sanghyun Lee, Brown University

Conjugate vaccine | DAY-2 Nov-14 | ROOM-A

Session Chair: Andrew Lees, CEO/CSO, Fina Biosolutions

08:00-08:30 Presentation Title: **Conjugation chemistry, carrier proteins and antigens: Promoting conjugate vaccine development**

Andrew Lees, CEO/CSO, Fina Biosolutions

08:30-09:00 Presentation Title: **Glycoconjugate vaccines to prevent AMR pathogens**

Roberto Adamo, Vaccine Development Leader, GSK

09:00-09:30 Presentation Title: **A conjugate vaccines targeting a genetic form of amyotrophic lateral sclerosis (C9orf72)**

Robert van der Put, Intravacc.nl

09:30-10:00 Presentation Title: **Preparation of bacterial polysaccharide-protein conjugate vaccines**

Wei Zou, National Research Council of Canada

Coffee Break 10:00-10:20

10:20-10:50 Presentation Title: **Conjugate vaccines for substance abuse**

Gary R. Matyas, US Military HIV Research Program, Walter Reed Army Institute of Research

10:50-11:20 Presentation Title: **Recent advancements in the glycoconjugate vaccines field**

Francesco Berti, GSK Vaccines,

11:20-11:50 Presentation Title: **Conjugation increases the immunogenicity and efficacy of T-cell inducing Glycolipid-Peptide (GLP) vaccines**

Gavin Painter, Victoria University Wellington

11:50-12:20

Presentation Title: **Peptide-glycolipid conjugate vaccines targeting Hepatitis B virus antigens**

Olivia Burn, Malaghan Institute of Medical Research

12:20-12:50 Presentation Title: **WISIT vaccines: Next generation vaccine platform leveraging skin immunity to treat chronic diseases**
Markus Mandler, Tridem Bioscience

Lunch Break 12:50-14:00

14:00-14:30 Presentation Title: **Development of a pneumococcal conjugate vaccine and novel vaccines through research driven efforts in India**
Ramesh Matur, Biological E Ltd

14:30-15:00 Presentation Title: **Rational design of a next-generation glycoconjugate vaccine inducing highly functional antibodies**
Giuseppe Stefanetti, Dipartimento di Scienze Biomolecolari, Università degli Studi di Urbino "Carlo Bo

Panel Session

Happy hours co-sponsored by



Coronavirus (COVID-19) | DAY-2 Nov-14 | ROOM-B

Session Chair: Shahin Gharakhanian, Decoy Therapeutics

08:00-08:20 MVA-vectored multi-antigen Covid-19 vaccines induce protective immunity against SARS-CoV-2 variants spanning Alpha to Omicron in preclinical animal models
Mukesh Kumar, Georgia State University

08:20-08:40 Superior mucosal B- and T-cell responses against SARS-CoV-2 after heterologous intramuscular mRNA prime/intranasal protein boost vaccination with a combination adjuvant
Michael Schotsaert, Icahn School of Medicine at Mount Sinai

08:40-09:00 Modular nanoarray vaccine for SARS-CoV-2
Yuri Lyubchenko, University of Nebraska Medical Center

09:00-09:20 Is a long-lasting COVID-19 vaccine feasible?
Gongyi zhang, National Jewish Health

09:20-09:40 Comparative efficacy of antiviral strategies targeting different stages of the viral life cycle

Barbara Jones, IBM Quantum

09:40-10:00 Intranasal Ad5 Omicron vaccine can build effective mucosal immunity wall against broad spectrum of SARS-CoV-2 variants

Ling Chen, Guangzhou Laboratory, Guangzhou Medical University

Coffee Break 10:00-10:20

10:20-10:40 Prevention of Covid-19 beyond the vaccine needle: Targeting transmission via development of a novel antiviral fusion peptide-based prophylactic nasal spray

Shahin Gharakhanian, Decoy Therapeutics

10:40-11:00 Durable immunity to SARS-CoV-2 infection and vaccination

Mehul Suthar, Emory University School of Medicine

11:00-11:20 Development of next generation vaccines against SARS-CoV-2 infection

Tian Wang, University of Texas Medical Branch

11:20-11:40 Minimalistic pan-coronavirus vaccines with a safer LNP delivery system and devoid of adverse spike epitopes

Janet K. Yamamoto, University of Florida

11:40-12:00 Selection for immune evasion in SARS-CoV-2 revealed by high-resolution epitope mapping and sequence analysis

Jorg Hermann Fritz, McGill University

12:00-12:20 Design of a subunit precision vaccine against SARS-CoV-2

M. Dahmani Fathallah, Arabian Gulf university

12-20-12:40

Lunch Break 12:40-13:40

New Vaccine Development | DAY-2 Nov-14 | ROOM-B

Session Chair: **John Shon**, Serimmune

13:40-14:00 Vaccines and monoclonal antibodies for treatment and prevention of opioid use disorders and opioid-related overdoses

Marco Pravetoni, University of Washington School of Medicine

14:00-14:20 Robust immunogenicity and protection with PlaCCine: A novel DNA vaccine delivered with a functionalized polymeric delivery system

Jean D Boyer, Imunon

- 14:20-14:40 Safety profile and analytical assessment of a cross-platform trivalent combination vaccine against invasive nontyphoidal salmonellosis and typhoid fever
Francesco Citiulo, GSK Vaccines Institute for Global Health
- 14:40-15:00 Development of a broadly cross-reactive vaccine against rhinoviruses
Sebastian L. Johnston, Imperial College London
- 15:00-15:20 Interrogation of human monoclonal antibodies induced by meningococcus B vaccination to identify cross-protective antigens against gonococcus
Oretta Finco, GSK (Bacterial Vaccines Unit)
- 15:20-15:40 SERA- universal serology enabling high-throughput, antigen agnostic studies of adaptive immune responses
John Shon, Serimmune
- Coffee Break 15:40-16:00
- 16:00-16:20 Correlative outcomes of maternal immunization against RSV in cotton rats
Jorge C. Blanco, Sigmovir Biosystems Inc.
- 16:20-16:40 CD40 ligand (CD40L)-based, dendritic cell-targeted vaccine (“FortiVac”) as a platform technology for high-level CD8+ T cell responses
Richard Kornbluth, Multimeric Biotherapeutics, Inc.
- 16:40-17:00 The respiratory syncytial virus G protein enhances the immune responses to the RSV F protein in an enveloped virus-like particle vaccine candidate
Trudy Morrison, University of Massachusetts Chan Medical School
- 17:00-17:20 Development of a pan-species/pan-disease T cell vaccine platform to address one health zoonotic risks
Thomas Tillett, MBF Therapeutics
- 17:20-17:40 mRNA vaccines against lassa virus
Alexander Bukreyev, University of Texas Medical Branch
- 17:40-18:00 Nanoparticle-based antigen favors high level of humoral immune responses and increases antigenicity of highly glycosylated protein
Yi Yang, Hunan Agricultural University
- 18:00-18:20 Development of a Marburgvirus subunit vaccine adjuvanted with a novel TLR7/TLR8 Agonist
Shweta Kailasan, Abvacc
- 18:20-18:40 ultraIPVTM: An improved polio vaccine
Stephen J. Dollery, Biological Mimetics, Inc

| **DAY-3 Nov-15** | **ROOM-A**

Session Chair:

Infectious & Non-Infectious Diseases

- 08:00-08:20 SchistoShield®, Sm-p80-based schistosomiasis vaccine: Human clinical trials in USA and Africa
Afzal A. Siddiqui, Texas Tech University Health Sciences Center
- 08:20-08:40 Development of an effective nontoxigenic *Clostridioides difficile* –based oral vaccine against *C. difficile* infection
Xingmin Sun, University of South Florida
- 08:40-09:00 *Ex vivo* antigen-loading of dendritic cells as a platform for personal cancer and infectious disease vaccines
Robert O. Dillman, AIVITA Biomedical, Inc
- 09:00-09:20 An ecosystem for the rapid generation of biological reagents against infectious diseases
Sumana Sundarmurthy, Sino Biological
- 09:20-09:40 DNA-based delivery of antiviral antibodies for infectious disease prevention
Rachel A. Liberatore, RenBio
- 09:40-10:00 Immune monitoring read outs when vector-based vaccines are used: including ELISPOT assays
Magdalena Tary-Lehmann, Cellular Technology Limited
- 10:00-10:20 The underlying genetic architecture of the immune system responsible for immunodominance
Stephen J Elledge, Harvard Medical School
- 10:20-10:40 How advances in artificial intelligence are optimizing the deployment and utilization of life-saving infectious disease countermeasures to high-consequence epidemics
Kamran Khan, BlueDot

Coffee Break 10:40-11:00

Cancer Vaccines & Immunotherapy

Session Chair: Farshad Guirakhoo, ExpreS2ion Biotechnology

- 11:00-11:20 Preclinical proof of concept studies of a novel human HER-2 virus like particle as a vaccine candidate for human breast cancers
Farshad Guirakhoo, ExpreS2ion Biotechnology
- 11:20-11:40 Exploring T-Cell pathways to enhance immunotherapies in cancer and infection
Christopher E. Rudd, Universite de Montreal
- 11:40-12:00 Stimulation of anti-tumor responses with small molecules that induce Z-DNA
Alan Herbert, InsideOutBio, Inc
- 12:00-12:20 Development of an enhanced IL-12-containing in situ vaccine for the treatment of solid tumor patients, refractory to anti-PD(L1) agents
Robert Hamilton Pierce, Attivare Therapeutics

Lunch Break 12:20-13:20

Influenza Vaccines

- 13:20-13:40 Approaches to enhance the generation of broadly reactive influenza-specific antibodies in newborns
Martha Alexander-Miller, Wake Forest University School of Medicine
- 13:40-14:00 Rapid development and flexible scale of complex recombinant proteins and antigens including ferritin nanoparticles for infectious diseases including COVID-19 and seasonal and pandemic influenza
Mark Emaflarb, Dyadic International Inc
- 14:00-14:20 Liposome-display of antigens: A powerful approach for vaccine development
Jonathan Lovell, University at Buffalo

Vaccine adjuvants

- 14:20-14:40 Immunomodulators identified via high-throughput screening enhance control of vaccine adjuvanticity
Matthew Rosenberger, University of Chicago
- 14:40-15:00 Adjuvantation with mRNA encoding IL-12 overcomes mRNA vaccine limitations
Byron Brook, Boston Children's Hospital
- 15:00-15:20 Harnessing sustained release technologies to produce robust, durable, and high-quality immunity
Eric Andrew Appel, Stanford University
- 15:20-15:40 mRNA vaccine against malaria tailored for liver-resident memory T cells
Gavin Painter, Victoria University Wellington
- 15:40-16:00 Development of saponin-based adjuvant IA-05 for subunit-vaccines
Pi-Hui Liang, Professor, School of Pharmacy, National Taiwan University, Founder and CEO of ImmunAdd, Inc. Taipei, Taiwan

Coffee Break 16:00-16:20

HIV Vaccine

Session Chair: Siddappa N. Byrareddy, University of Nebraska Medical Center

- 16:20-16:40 Induction of CD4-mimicking HIV-1 broadly neutralizing antibody precursors in macaques with protein and mRNA vaccination
Kevin O. Saunders, Duke Human Vaccine Institute
- 16:40-17:00 HIV clade C vaccine adjuvanted with NE/AS01B in SHIV-challenged macaques
Siddappa N. Byrareddy, University of Nebraska Medical Center
- 17:00-17:20 Vaccination with immune complexes modulates the elicitation of functional antibodies against HIV-1
Catarina Hioe, Icahn School of Medicine at Mount Sinai

- 17:20-17:40 Antiviral vaccine route and form potentially impact immunogenicity and efficacy
Mark Connors, NIAID/LIR
- 17:40-18:00 Synergy between tissue resident memory CD8 T cells and antibody for protection against HIV
Rama Rao Amara, Emory National Primate Research Center

Note: This is a tentative program subject to change

